{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:42:53Z","timestamp":1791506573402,"version":"4.3.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.canrad.2023.06.017","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:43:31Z","timestamp":1693554211000},"page":"511-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lymphop\u00e9nie radio-induite\u00a0: les lymphocytes comme nouvel organe \u00e0 risque"],"prefix":"10.1016","volume":"27","author":[{"given":"P.A.","family":"Laurent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9.","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2023.06.017_bib0535","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib0540","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib0545","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/j.cllc.2021.10.008","article-title":"PD-1\u00a0inhibitor and chemotherapy with concurrent irradiation at varied tumor sites in advanced non-small cell lung cancer: the prospective randomized phase 3\u00a0NIRVANA-lung trial","volume":"23","author":"Doyen","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.canrad.2023.06.017_bib0550","doi-asserted-by":"crossref","first-page":"e001001","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canrad.2023.06.017_bib0555","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12885-019-5266-4","article-title":"Phase I\/II trial of durvalumab plus tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma","volume":"19","author":"Bahig","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canrad.2023.06.017_bib0560","doi-asserted-by":"crossref","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35\u00a0Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0565","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.annonc.2022.10.006","article-title":"Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01\u00a0PembroRad): a multicenter, randomized, phase II trial","volume":"34","author":"Tao","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0570","doi-asserted-by":"crossref","first-page":"S1399","DOI":"10.1016\/j.annonc.2022.08.029","article-title":"LBA5\u00a0Primary results of the phase III KEYNOTE-412\u00a0study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs. placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)","volume":"33","author":"Machiels","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0575","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3\u00a0trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0580","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.6008","article-title":"Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC)","volume":"39","author":"Uppaluri","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0585","doi-asserted-by":"crossref","first-page":"e002568","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358\u00a0trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canrad.2023.06.017_bib0590","doi-asserted-by":"crossref","first-page":"100426","DOI":"10.1016\/j.xcrm.2021.100426","article-title":"Neoadjuvant presurgical PD-1\u00a0inhibition in oral cavity squamous cell carcinoma","volume":"2","author":"Knochelmann","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib0595","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.radonc.2021.02.029","article-title":"Hematological toxicity in patients with solid malignant tumors treated with radiation\u00a0\u2013\u00a0temporal analysis, dose response and impact on survival","volume":"158","author":"Terrones-Campos","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0600","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.02.023","article-title":"Survival fraction at 2Gy and \u03b3H2AX expression kinetics in peripheral blood lymphocytes from cancer patients: relationship with acute radiation-induced toxicities","volume":"92","author":"Pouliliou","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0605","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4\u00a0or CD8\u00a0positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2023.06.017_bib0610","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.6004\/jnccn.2015.0151","article-title":"Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors","volume":"13","author":"Grossman","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.canrad.2023.06.017_bib0615","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1016\/j.ijrobp.2016.06.2512","article-title":"Chemoradiation-related lymphopenia is common among glioblastoma patients and is associated with worse progression-free and overall survival","volume":"96","author":"Rahman","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0620","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-015-2037-1","article-title":"Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma","volume":"127","author":"Mendez","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0625","doi-asserted-by":"crossref","DOI":"10.1002\/hed.24158","article-title":"Minimum absolute lymphocyte count during radiotherapy as a new prognostic factor for nasopharyngeal cancer: lymphopenia during RT in nasopharyngeal cancer","volume":"38","author":"Cho","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.canrad.2023.06.017_bib0630","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4143\/crt.2016.595","article-title":"The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients","volume":"50","author":"Liu","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.canrad.2023.06.017_bib0635","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/hed.23535","article-title":"Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer: treatment-related lymphopenia in head and neck cancer","volume":"36","author":"Campian","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.canrad.2023.06.017_bib0640","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1016\/j.ijrobp.2016.06.1831","article-title":"Lymphocyte depletion by radiation therapy alone is associated with poor survival in non-small cell lung cancer","volume":"96","author":"Joo","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0645","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","article-title":"Lymphopenia association with gross tumor volume and lung V5\u00a0and its effects on non-small cell lung cancer patient outcomes","volume":"89","author":"Tang","year":"2014","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0650","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.ijrobp.2016.06.366","article-title":"Circulating Lymphocyte count during neoadjuvant chemoradiation therapy for esophageal cancer as a predictive biomarker of pathologic complete response","volume":"96","author":"Jiang","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0655","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.4_suppl.137","article-title":"The impact of proton beam therapy on blood cell count nadir during neoadjuvant chemoradiation therapy for esophageal cancer","volume":"35","author":"Shiraishi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0660","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/07357907.2012.700987","article-title":"The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas","volume":"30","author":"Balmanoukian","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.canrad.2023.06.017_bib0665","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/COC.0b013e3182940ff9","article-title":"The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma","volume":"38","author":"Wild","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0670","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ygyno.2015.11.013","article-title":"Lymphopenia and its association with survival in patients with locally advanced cervical cancer","volume":"140","author":"Wu","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0675","first-page":"3541","article-title":"Prognostic value of severe lymphopenia during pelvic concurrent chemoradiotherapy in cervical cancer","volume":"36","author":"Cho","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2023.06.017_bib0680","doi-asserted-by":"crossref","first-page":"101038","DOI":"10.1016\/j.adro.2022.101038","article-title":"Meta-analysis and critical review: association between radio-induced lymphopenia and overall survival in solid cancers","volume":"8","author":"El Houat","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0685","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.radonc.2021.12.038","article-title":"On the interplay between dosiomics and genomics in radiation-induced lymphopenia of lung cancer patients","volume":"167","author":"Monti","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0690","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-0042-1753504","article-title":"A systematic review and meta-analysis of the impact of radiation-related lymphopenia on outcomes in high-grade gliomas","volume":"11","author":"Mallick","year":"2022","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.canrad.2023.06.017_bib0695","doi-asserted-by":"crossref","first-page":"768811","DOI":"10.3389\/fimmu.2022.768811","article-title":"Potential determinants for radiation-induced lymphopenia in patients with breast cancer using interpretable machine learning approach","volume":"13","author":"Yu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0700","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3389\/fonc.2019.01488","article-title":"Prognosis and risk factors of radiation-induced lymphopenia in early-stage lung cancer treated with stereotactic body radiation therapy","volume":"9","author":"Zhao","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0705","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2020.09.002","article-title":"Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1\u00a0rs25487\u00a0genotypes in lymphocytes","volume":"154","author":"Xie","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0710","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2022.10.019","article-title":"Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): a systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy","volume":"177","author":"Venkatesulu","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0715","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.jtho.2020.06.008","article-title":"Radiotherapy-Related lymphopenia affects overall survival in patients with lung cancer","volume":"15","author":"Abravan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0720","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.radonc.2020.05.051","article-title":"Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy","volume":"150","author":"Chen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0725","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.radonc.2020.09.002","article-title":"Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1\u00a0rs25,487\u00a0genotypes in lymphocytes","volume":"154","author":"Xie","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0730","first-page":"54","article-title":"Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: results of a long-term follow up study","volume":"28","author":"Jing","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0735","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2020.12.019","article-title":"Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: a comparative analysis of proton versus photon therapy","volume":"156","author":"Kim","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0740","doi-asserted-by":"crossref","first-page":"E206","DOI":"10.1016\/j.ijrobp.2019.06.2041","article-title":"Dose to heart, spine, aorta, and body predict for severe lymphopenia and poor survival in patients undergoing chemoradiation for esophageal cancer","volume":"105","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0745","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1002\/onco.13533","article-title":"Lymphopenia during definitive chemoradiotherapy in esophageal squamous cell carcinoma: association with dosimetric parameters and patient outcomes","volume":"26","author":"Xu","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.canrad.2023.06.017_bib0750","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3389\/fonc.2020.00997","article-title":"Low lymphocyte count is associated with radiotherapy parameters and affects the outcomes of esophageal squamous cell carcinoma patients","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol juin"},{"key":"10.1016\/j.canrad.2023.06.017_bib0755","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.346","article-title":"Correlation of heart dose with lymphopenia in esophageal cancer patients treated with chemoradiation","volume":"38","author":"Post","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0760","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.radonc.2020.02.015","article-title":"The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy","volume":"146","author":"Xu","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0765","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ijrobp.2015.04.005","article-title":"Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma","volume":"92","author":"Huang","year":"2015","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0770","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijrobp.2018.01.069","article-title":"Effect of radiation treatment volume reduction on lymphopenia in patients receiving chemoradiotherapy for glioblastoma","volume":"101","author":"Rudra","year":"2018","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0775","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13014-019-1256-6","article-title":"Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era","volume":"14","author":"Byun","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0780","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11060-019-03146-7","article-title":"Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients","volume":"143","author":"Hui","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0785","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/cam4.2159","article-title":"Dosimetry of the brain and hypothalamus predicting acute lymphopenia and the survival of glioma patients with postoperative radiotherapy","volume":"8","author":"Ye","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib0790","first-page":"284","article-title":"Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs. photons","volume":"23","author":"Mohan","year":"2021","journal-title":"Neurooncology"},{"key":"10.1016\/j.canrad.2023.06.017_bib0795","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.21873\/invivo.11409","article-title":"Spleen Dose\u00a0\u2013\u00a0volume parameters as a predictor of treatment-related lymphopenia during definitive chemoradiotherapy for esophageal cancer","volume":"32","author":"Saito","year":"2018","journal-title":"In Vivo"},{"key":"10.1016\/j.canrad.2023.06.017_bib0800","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.adro.2018.09.004","article-title":"A comparison of grade 4\u00a0lymphopenia with proton versus photon radiation therapy for esophageal cancer","volume":"4","author":"Routman","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0805","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.21037\/tcr-21-1765","article-title":"Association between unintentional splenic radiation and lymphopenia and high neutrophil\/lymphocyte ratio after radiotherapy in patients with esophageal cancer","volume":"10","author":"Sakaguchi","year":"2021","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.canrad.2023.06.017_bib0810","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.radonc.2019.12.008","article-title":"Mean cardiopulmonary dose and vertebral marrow dose differentially predict lineage-specific leukopenia kinetics during radiotherapy for esophageal cancer","volume":"152","author":"Anderson","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0815","doi-asserted-by":"crossref","first-page":"100545","DOI":"10.1016\/j.adro.2020.08.002","article-title":"Patient-specific lymphocyte loss kinetics as biomarker of spleen dose in patients undergoing radiation therapy for upper abdominal malignancies","volume":"6","author":"Yalamanchali","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0820","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.2147\/CMAR.S297010","article-title":"The impact of lymphopenia and dosimetric parameters on overall survival of esophageal cancer patients treated with definitive radiotherapy","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.canrad.2023.06.017_bib0825","doi-asserted-by":"crossref","first-page":"rrab094","DOI":"10.1093\/jrr\/rrab094","article-title":"The impact of lymphopenia during chemoradiotherapy using photons or protons on the clinical outcomes of esophageal cancer patients","author":"Sumiya","year":"2021","journal-title":"J Radiat Res (Tokyo)"},{"key":"10.1016\/j.canrad.2023.06.017_bib0830","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.21037\/jtd.2020.03.93","article-title":"Dosimetric analysis of lymphopenia during chemoradiotherapy for esophageal cancer","volume":"12","author":"Newman","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.canrad.2023.06.017_bib0835","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12957-019-1747-9","article-title":"Association of pre-surgery to pre-radiotherapy lymphocyte counts ratio with disease-free survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy","volume":"17","author":"Xu","year":"2019","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0840","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.adro.2018.08.014","article-title":"Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors","volume":"3","author":"Ellsworth","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0845","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/CCI.21.00098","article-title":"Identifying individualized risk profiles for radiotherapy-induced lymphopenia among patients with esophageal cancer using machine learning","volume":"5","author":"Zhu","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.canrad.2023.06.017_bib0850","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer","volume":"94","author":"Wild","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0855","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40425-016-0149-6","article-title":"A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"4","author":"Crocenzi","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.canrad.2023.06.017_bib0860","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s12094-018-1851-2","article-title":"Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients","volume":"20","author":"Yuan","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0865","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2020.04.054","article-title":"Ultra-high dose rate effect on circulating immune cells: a potential mechanism for flash effect?","volume":"149","author":"Jin","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0870","doi-asserted-by":"crossref","first-page":"20211150","DOI":"10.1259\/bjr.20211150","article-title":"Flash irradiation induces lower levels of DNA damage ex vivo, an effect modulated by oxygen tension, dose, and dose rate","volume":"95","author":"Cooper","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0875","doi-asserted-by":"crossref","first-page":"17180","DOI":"10.1038\/s41598-019-53562-y","article-title":"Ultra high dose rate (35Gy\/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome","volume":"9","author":"Venkatesulu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.canrad.2023.06.017_bib0880","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1002\/mp.15680","article-title":"Radioprotective effect of X-ray abdominal FLASH irradiation: adaptation to oxidative damage and inflammatory response may be benefiting factors","volume":"49","author":"Zhu","year":"2022","journal-title":"Med Phys"},{"key":"10.1016\/j.canrad.2023.06.017_bib0885","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41571-022-00697-z","article-title":"Towards clinical translation of flash radiotherapy","volume":"19","author":"Vozenin","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0905","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.prro.2019.07.010","article-title":"Prediction of severe lymphopenia during chemoradiation therapy for esophageal cancer: development and validation of a pretreatment nomogram","volume":"10","author":"van Rossum","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0895","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canrad.2023.06.017_bib0890","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2021.06.020","article-title":"Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC","volume":"162","author":"Yu","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0900","doi-asserted-by":"crossref","first-page":"768956","DOI":"10.3389\/fonc.2022.768956","article-title":"Radiation induced lymphopenia is associated with the effective dose to the circulating immune cells in breast cancer","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0910","doi-asserted-by":"crossref","first-page":"035014","DOI":"10.1088\/1361-6560\/ab63b6","article-title":"A novel deep learning model using dosimetric and clinical information for grade 4\u00a0radiotherapy-induced lymphopenia prediction","volume":"65","author":"Zhu","year":"2020","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0915","doi-asserted-by":"crossref","first-page":"905222","DOI":"10.3389\/fonc.2022.905222","article-title":"A machine learning model for grade 4\u00a0lymphopenia prediction during pelvic radiotherapy in patients with cervical cancer","volume":"12","author":"Xu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0920","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1667\/RR2536.1","article-title":"MOSFET assessment of radiation dose delivered to mice using the Small Animal Radiation Research Platform (SARRP)","volume":"176","author":"Ngwa","year":"2011","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2023.06.017_bib0925","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.ijrobp.2008.04.025","article-title":"High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities","volume":"71","author":"Wong","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0930","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1118\/1.3533947","article-title":"Characterization of image quality and image-guidance performance of a preclinical microirradiator: characterization of a preclinical microirradiator","volume":"38","author":"Clarkson","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.canrad.2023.06.017_bib0935","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.zemedi.2014.07.004","article-title":"Pre-clinical research in small animals using radiotherapy technology\u00a0\u2013\u00a0a bidirectional translational approach","volume":"24","author":"Tillner","year":"2014","journal-title":"Z F\u00fcr Med Phys"},{"key":"10.1016\/j.canrad.2023.06.017_bib0940","first-page":"112","article-title":"A scoping review of small animal image-guided radiotherapy research: advances, impact and future opportunities in translational radiobiology","volume":"34","author":"Brown","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.canrad.2023.06.017_bib0945","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1118\/1.4747261","article-title":"Dosimetric properties of radiophotoluminescent glass detector in low-energy photon beams: properties of RGD in low-energy photons","volume":"39","author":"Kadoya","year":"2012","journal-title":"Med Phys"},{"key":"10.1016\/j.canrad.2023.06.017_bib0950","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-15-2784","article-title":"Immuno-PET imaging of engineered human T cells in tumors","volume":"76","author":"Mall","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2023.06.017_bib0955","doi-asserted-by":"crossref","first-page":"eaag2196","DOI":"10.1126\/scitranslmed.aag2196","article-title":"Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma","volume":"9","author":"Keu","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib0960","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.7150\/thno.17994","article-title":"In-depth characterization of a TCR-specific tracer for sensitive detection of tumor-directed transgenic T cells by immuno-PET","volume":"7","author":"Yusufi","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.canrad.2023.06.017_bib0965","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2967\/jnumed.116.173930","article-title":"Quantitative CD3\u00a0PET imaging predicts tumor growth response to anti-CTLA-4\u00a0therapy","volume":"57","author":"Larimer","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib0970","doi-asserted-by":"crossref","first-page":"e0193832","DOI":"10.1371\/journal.pone.0193832","article-title":"Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89\u00a0radiolabeled anti-CD3\u00a0antibody in immune-competent mice bearing syngeneic tumors","volume":"13","author":"Beckford Vera","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.canrad.2023.06.017_bib0975","first-page":"852","article-title":"Implementation of 89Zr production and in vivo imaging of B-cells in mice with 89Zr-labeled anti-B-cell antibodies by small animal PET\/CT","volume":"69","author":"Walther","year":"2011","journal-title":"Appl Radiat Isot Data Instrum Methods Use Agric Ind Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib0980","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2967\/jnumed.114.152918","article-title":"In vivo imaging of natural killer cell trafficking in tumors","volume":"56","author":"Galli","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib0985","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1158\/1078-0432.CCR-19-2897","article-title":"In vivo tracking of adoptively transferred natural killer cells in rhesus macaques using (89zirconium)-oxine cell labeling and PET imaging","volume":"26","author":"Sato","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canrad.2023.06.017_bib0990","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2967\/jnumed.115.156828","article-title":"PET Imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using (18F)-radiolabeled camelid single-domain antibody fragments","volume":"56","author":"Blykers","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib0995","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s11307-018-01302-5","article-title":"Clinical translation of (68Ga)-Ga-NOTA-anti-MMR-sdAb for PET\/CT imaging of protumorigenic macrophages","volume":"21","author":"Xavier","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.canrad.2023.06.017_bib1000","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2967\/jnumed.118.220350","article-title":"Small-animal PET\/CT imaging of local and systemic immune response using 64Cu-\u03b1CD11b","volume":"60","author":"Cao","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib1005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11307-019-01427-1","article-title":"Preclinical immunoPET imaging of glioblastoma-infiltrating myeloid cells using zirconium-89\u00a0labeled anti-CD11b antibody","volume":"22","author":"Nigam","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.canrad.2023.06.017_bib1010","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s11307-017-1060-3","article-title":"Development of novel immunoPET tracers to image human PD-1\u00a0checkpoint expression on tumor-infiltrating lymphocytes in a humanized mouse model","volume":"19","author":"Natarajan","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.canrad.2023.06.017_bib1015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2967\/jnumed.116.177857","article-title":"Preclinical pharmacokinetics and biodistribution studies of (89Zr-)labeled pembrolizumab","volume":"58","author":"England","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib1020","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.bmc.2017.07.066","article-title":"Radiosynthesis and preclinical PET evaluation of (89Zr)-nivolumab (BMS-936558) in healthy non-human primates","volume":"25","author":"Cole","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.canrad.2023.06.017_bib1025","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2967\/jnumed.117.191718","article-title":"In vivo imaging of the programmed death ligand 1\u00a0by (18F)-PET","volume":"58","author":"Gonz\u00e1lez Trotter","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib1030","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1021\/acs.molpharmaceut.8b00062","article-title":"Immuno-PET imaging of 89\u00a0Zr labeled anti-PD-L1\u00a0domain antibody","volume":"15","author":"Li","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.canrad.2023.06.017_bib1035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2967\/jnumed.119.226712","article-title":"PET imaging of tumor PD-L1\u00a0expression with a highly specific nonblocking single-domain antibody","volume":"61","author":"Lv","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.canrad.2023.06.017_bib1040","first-page":"53","article-title":"Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models","volume":"9","author":"Ehlerding","year":"2019","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.canrad.2023.06.017_bib1045","doi-asserted-by":"crossref","first-page":"e109866","DOI":"10.1371\/journal.pone.0109866","article-title":"et al., 64Cu-DOTA-anti-CTLA-4\u00a0mAb enabled PET visualization of CTLA-4\u00a0on the T-cell infiltrating tumor tissues","volume":"9","author":"Higashikawa","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.canrad.2023.06.017_bib1050","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1073\/pnas.1801524115","article-title":"Anti-CTLA-4\u00a0therapy requires an Fc domain for efficacy","volume":"115","author":"Ingram","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.canrad.2023.06.017_bib1055","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1038\/s41467-018-07131-y","article-title":"Whole body PD-1\u00a0and PD-L1\u00a0positron emission tomography in patients with non-small-cell lung cancer","volume":"9","author":"Niemeijer","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.canrad.2023.06.017_bib0530","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s40425-019-0607-z","article-title":"PD-L1\u00a0detection using (89Zr)-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response","volume":"7","author":"Vento","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823001312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321823001312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:38:46Z","timestamp":1761136726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321823001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":106,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1278321823001312"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2023.06.017","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphop\u00e9nie radio-induite\u00a0: les lymphocytes comme nouvel organe \u00e0 risque","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2023.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO).","name":"copyright","label":"Copyright"}]}}